Multimodality treatment of recurrent XXXX : Mith or reality?

@entity1 @entity3123 @entity788 @entity66 @entity146 @entity5
@entity788 is the fourth cause of @entity5 in the United States. Surgery is the only potentially curative treatment, but most @entity1 present at diagnosis with unresectable or metastatic disease. Moreover, even with an R0 resection, the majority of @entity1 will die of disease recurrence. Most recurrences occur in the first 2-year after pancreatic resection, and are commonly located in the abdomen, even if distant metastases can occur. Recurrent @entity788 remains a significant therapeutic challenge, due to the limited role of surgery and radio-chemotherapy. Surgical management of recurrence is usually unreliable because @entity5 relapse typically presents as a technically unresectable, or as @entity66 with an @entity146 growth. Therefore, treatment of @entity1 with recurrent @entity788 has historically been limited to palliative chemotherapy or supportive care. Only few data are available in the Literature about this issue, even if in recent years more studies have been published to determine whether treatment after recurrence have any effect on @entity1 outcome. Recent therapeutic advances have demonstrated the potential to improve survival in selected @entity1 who had undergone resection for @entity788 . Multimodality management of recurrent @entity3123 may lead to better survival and quality of life in a small but significant percentage of @entity1 ; however, more and larger studies are needed to clarify the role of the different therapeutic options and the optimal way to combine them.
